

CAPLIN POINT LABORATORIES LIMITED

Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096
 CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE PERIOD ENDED 31st DECEMBER 2020

Prepared in compliance with the Indian Accounting Standards (Ind - AS)


Particulars	Three Months Ended			Nine Months Ended		Financial Year Ended
	31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
	(1)	(2)	(3)	(4)	(5)	(6)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INR in Crs					
Income:						
I Revenue from operations	274.39	268.12	228.21	782.58	647.97	863.20
II Other income	5.82	1.76	10.34	14.08	21.70	41.33
III Total Income (I+II)	280.21	269.88	238.55	796.66	669.67	904.53
IV Expenses:						
a. Cost of materials consumed	37.21	31.99	25.89	90.38	84.31	108.12
b. Purchase of traded goods	50.81	81.85	96.06	156.29	290.75	500.14
c. Changes in inventories of finished goods, stock in trade and work in progress	35.88	6.52	(14.83)	106.39	(73.33)	(195.10)
d. Employee benefit expenses	25.51	25.27	17.68	76.66	49.23	67.76
e. Finance cost	0.28	0.48	0.06	1.27	0.15	0.32
f. Depreciation & Amortisation Expenses	9.27	8.88	8.42	27.11	23.22	31.62
g. Other Expenses	41.05	35.06	35.65	109.92	90.75	122.21
h. Total Expenses	200.01	190.05	168.93	568.02	465.08	635.07
V Profit before exceptional items and Tax (III-IV)	80.20	79.83	69.62	228.64	204.59	269.46
VI Exceptional items	-	-	-	-	-	-
VII Profit Before Tax (V-VI)	80.20	79.83	69.62	228.64	204.59	269.46
VIII Tax Expenses						
(1) Current Tax	16.67	20.08	15.83	54.54	43.67	61.84
(2) Deferred Tax (Refer Note 4)	(2.61)	(3.08)	(5.10)	(9.41)	(5.30)	(7.46)
Total Tax Expenses	14.06	17.00	10.73	45.13	38.37	54.38
IX Net Profit for the period (VII - VIII)	66.14	62.83	58.88	183.51	166.22	215.08
X Other Comprehensive Income - Net of Tax						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	-	0.61	0.00	0.61	(0.40)	(0.70)
ii) Surplus on acquisition of subsidiary	-	-	-	-	-	1.99
B. Items that will be re-classified to profit or loss						
i) Exchange difference in translating the financial statements of foreign operations	(3.36)	(6.62)	1.21	(9.99)	5.76	15.39
XI Total Comprehensive Income For The Period (IX + X)	62.78	56.82	60.10	174.13	171.58	231.76
XII Profit attributable to:						
Owners of the Company	64.46	56.89	58.56	175.89	166.11	215.00
Non- controlling interests	1.68	5.94	0.32	7.62	0.11	0.08
	66.14	62.83	58.88	183.51	166.22	215.08
XIII Total Comprehensive Income For The Period attributable to						
Owners of the Company	61.11	50.88	59.78	166.51	171.47	231.68
Non- controlling Interests	1.67	5.94	0.32	7.62	0.11	0.08
	62.78	56.82	60.10	174.13	171.58	231.76
XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.13	15.13	15.13	15.13	15.13	15.13
XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	858.2
XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share						
(a) Basic (in Rupees)	8.52	7.52	7.74	23.25	21.96	28.42
(b) Diluted (in Rupees)	8.46	7.46	7.68	23.07	21.79	28.20



Notes :

- 1) The above consolidated financial results for the quarter and nine months ended December 31, 2020 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 4th February, 2021
- 2) The consolidated financial results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The Company elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended 31st March, 2020 and remeasured its deferred tax assets and liabilities basis the rates prescribed in the said section. The Company recognized an amount of Rs. 563.90 Lacs towards reversal of deferred tax liability(net) during the year ended 31st March, 2020 on account of the remeasurement for entities based in India
- 5) During the Quarter and nine months ended December 31, 2020 the Company has allotted NIL equity shares of Rs. 2/- each under the Employees Stock Option Scheme 2015 as against allotment of NIL equity shares in the quarter ended December 31, 2019 and allotment of 12500 equity shares in the nine months ended December,31 2019.
- 6) Revenue from operations is disclosed net of Goods & Service Tax/ Value Added Tax as applicable
- 7) As the out-break continues to evolve,the Group will closely monitor any material changes to future economic conditions. Based on the assessment done by the management of the Company,there is no significant/material impact of COVID-19 on the results for the quarter and nine months ended December 31,2020.
- 8) The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015. An unqualified opinion has been issued by them thereon.
- 9) As the Parent Company's wholly owned subsidiary Caplin Point Far East Limited, Hong Kong had acquired subsidiaries in Nicaragua (in Q1),Honduras (in Q2),Ecuador and Guatemala (in Q4) in FY 19-20, the current quarter results and the nine month results are not comparable with the previous periods.
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.

For and on behalf of the Board



Dr. Sridhar Ganesan
Managing Director

Place: Chennai

Date: 4th February,2021



CAPLIN POINT LABORATORIES LIMITED

Registered Office: 3rd Floor, "Ashvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE PERIOD ENDED 31st DECEMBER 2020

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

	Particulars	Three Months Ended			Nine Months Ended		Financial Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(1)	(2)	(3)	(4)	(5)	(6)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
INR In Crs							
	Income:						
I	Revenue from operations	123.16	116.92	154.17	359.80	427.70	527.83
II	Other income (Refer Note 5)	3.98	3.24	8.43	11.26	32.96	65.97
III	Total Income (I+II)	127.14	120.16	162.60	371.06	460.66	593.80
	Expenses:						
	a. Cost of materials consumed	32.05	28.63	24.00	79.51	75.35	95.73
	b. Purchase of traded goods	13.28	23.09	46.22	62.72	113.84	143.18
	c. Changes in inventories of finished goods, stock in trade and work in progress	2.77	(7.51)	0.76	(1.16)	2.62	(0.74)
	d. Employee benefit expenses	7.34	5.72	6.90	19.28	20.24	25.00
	e. Finance cost	0.04	0.04	0.05	0.13	0.13	0.18
	f. Depreciation & Amortisation Expenses	5.61	5.43	5.30	16.47	13.98	19.65
	g. Other Expenses	10.74	10.77	18.78	28.81	47.20	57.66
	h. Total Expenses	71.83	66.17	102.01	205.76	273.35	340.66
V	Profit before exceptional items and Tax (III-IV)	55.31	53.99	60.59	165.30	187.31	253.14
VI	Exceptional items	-	-	-	-	-	-
VII	Profit Before Tax (V-VI)	55.31	53.99	60.59	165.30	187.31	253.14
VIII	Tax Expenses						
	(1) Current Tax	14.07	13.21	14.86	41.76	40.21	55.89
	(2) Deferred Tax (Refer Note 4)	(0.24)	(0.48)	(1.86)	(1.20)	(0.39)	(0.40)
	Total Tax Expenses	13.83	12.73	13.00	40.56	39.82	55.49
IX	Net Profit for the period (VII-VIII)	41.48	41.26	47.59	124.73	147.49	197.65
X	Other Comprehensive Income/ (Loss) - Net of Tax						
	A. Items that will not be re-classified to profit or loss						
	i) Remeasurements of Defined Benefit Plan	-	-	(0.06)	0.38	(0.25)	(0.33)
XI	Total Comprehensive Income For The Period (IX+X)	41.48	41.26	47.53	125.11	147.24	197.32
XII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.13	15.13	15.13	15.13	15.13	15.13
XIII	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	584.78
XIV	Earnings Per Share (EPS) based on face value Rs 2/- per Equity share						
	(a) Basic (in Rupees)	5.48	5.45	6.29	16.49	19.50	26.13
	(b) Diluted (in Rupees)	5.45	5.42	6.25	16.38	19.37	25.95
		(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	Annualised




Notes :

- 1) The above standalone financial results for the quarter and nine months ended December 31, 2020 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on 4th February, 2021
- 2) The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (" the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The Company elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended 31st March, 2020 and remeasured its deferred tax liabilities basis the rates prescribed in the said section. The Company recognized an amount of Rs. 630.63 Lacs towards reversal of deferred tax liability during the year ended 31st March, 2020 on account of the remeasurement
- 5) Other Income and Profits Before Tax for the Nine month ended December 31,2020 includes Dividend of Rs. 3.05 Crs (received in quarter ended 30th Sep' 2020) as against Rs.17.53 Crs (received in quarter ended 30th Sep' 2019) for the same period last year ,received from our wholly owned subsidiary Caplin Point Far East Limited, Hong Kong.
- 6) Revenue from operations is disclosed net of Goods and Service Tax
As the out-break continues to evolve,the company will closely monitor any material changes to future economic conditions.Based on the
7) assessment done by the management of the Company,there is no significant/material impact of COVID-19 on the results for the quarter and nine months ended December 31,2020

The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to regulation 33 of
8) the SEBI (Listing obligations & Disclosure Requirements) Regulations,2015. An unqualified opinion has been issued by them thereon.

During the Quarter and nine months ended December 31, 2020 the Company has allotted NIL equity shares of Rs. 2/- each under the Employees
9) Stock Option Scheme 2015 as against allotment of NIL equity shares in the quarter ended December 31, 2019 and allotment of 12500 equity shares in the nine months ended December,31 2019
- 10) Prior year / period figures are regrouped / rearranged wherever necessary.

For and on behalf of the Board



Dr. Sridhar Ganesan
Managing Director

Place: Chennai

Date: 4th February,2021

